한국어
English
日本語
中文(简体)
Zelboraf Tablets 240 mg (Vemurafenib)
800mg
Tablet · Prescription medication
Korea Roche Co., Ltd.
Bemurafenib solid dispersion is an anticancer ingredient used for the treatment of BRAF mutant melanoma.
MFDS ingredient code M282778
Bemurafenib solid dispersion is an anticancer ingredient that targets the BRAF V600 mutation. It is mainly used to inhibit the growth of cancer cells in specific cancers such as melanoma. It is formulated as a solid dispersion to enhance bioavailability.
Bemurafenib solid dispersion binds to the mutated part of the BRAF protein inside cancer cells, blocking signaling pathways. This leads to the inhibition of the pathways necessary for cancer cell proliferation and survival, effectively stopping the growth of cancer cells.
Approved uses differ by product. Check each product's information for its actual use.
Bemurafenib solid dispersion is characterized by its selective inhibition of the BRAF V600 mutation. Unlike other anticancer agents, it serves as a targeted therapy tailored to specific genetic mutations, distinguishing itself in terms of side effects and efficacy.
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, dosage and approved uses can differ by strength, dosage form and combined ingredients. Check each product's information before taking it.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
Product approval information is based on drug information provided by the Ministry of Food and Drug Safety.
Ingredient and class descriptions are not part of MFDS data and were written separately by Cashdoc.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.